Ionis Pharmaceuticals
4 articles
Industry NewsIonis Pharmaceuticals / Arrowhead PharmaceuticalsBioSpace
Ionis's weak Tryngolza launch clouds Arrowhead's severe-hypertriglyceridemia bet
- Ionis reported flat Tryngolza sales of $9M and cut 2026 sales guidance to $50M, citing a slower ramp; Stifel said it was worse than already low expectations.
- Arrowhead's Redemplo earned $6.6M in its first full fiscal year after its November 2025 approval in FCS; Arrowhead has filed it in severe hypertriglyceridemia (sHTG) and joined FDA's STAR pilot.
- CEO Chris Anzalone blamed Ionis's communication and execution rather than the market; Jefferies sees up to $2.5B in sales but calls the near term tricky.
Both drugs are tuned to the same triglyceride-lowering story, so Ionis's slow FCS launch is a fair read-across for Arrowhead's rare-disease start, but the real bet is sHTG, where the patient pool is orders of magnitude larger and the buyer is a cardiologist, not a rare-disease center. Arrowhead's answer is execution; what it needs to show is a pancreatitis-prevention story that payers will pay for, not just lower lipids.
Industry NewsNovartis / Ionis PharmaceuticalsSTAT News
Pelacarsen Full Data at AHA: Lp(a) Down, Events Not
- Novartis presented the full Lp(a)HORIZON results at the AHA meeting, with simultaneous NEJM publication. The antisense drug, licensed from Ionis, sharply lowered Lp(a) but did not reduce cardiovascular events versus placebo over nearly five years.
- The topline miss was disclosed in September; the full data leave the trial leader saying many in the field will be left scratching their heads.
This is the first large test of the Lp(a) hypothesis and it did not pay off, which hits the whole class: Amgen's olpasiran and Lilly's lepodisiran are running similar outcomes trials on the same premise. Two things to watch: whether the degree of Lp(a) lowering, not just direction, matters, and whether a subgroup with very high baseline Lp(a) tells a different story.
Industry NewsIonis Pharmaceuticals / RocheEndpoints News
Sefaxersen Hits Primary Endpoint in Phase 3 IgA Nephropathy Trial, Opening Path to Accelerated Approval
- Sefaxersen, Ionis's antisense oligonucleotide suppressing liver complement factor B, met the primary endpoint of Roche's Phase 3 IMAgINATION trial in high-risk primary IgA nephropathy.
- A prespecified interim analysis of 459 patients (1:1 randomized) showed statistically significant, clinically meaningful proteinuria reduction (24-hour UPCR) vs. placebo at week 37.
- The once-monthly, self-administered subcutaneous drug could support accelerated approval in a crowded IgAN market that already includes sparsentan.
Complement factor B suppression becomes a third distinct mechanism validated in IgA nephropathy, joining sparsentan's endothelin/AT1 blockade and the B-cell/APRIL plays from atacicept and sibeprenlimab; convergent proteinuria data across mechanisms suggests the market fragments by dosing convenience, not efficacy. Once-monthly self-injection undercuts daily oral and infused rivals on adherence, while Ionis banks another platform-licensing win validating its originate-and-out-license model.
Industry NewsNovartis / Ionis PharmaceuticalsSTAT News
Novartis' Lp(a)-lowering drug pelacarsen fails cardiovascular outcomes trial
- Novartis' pelacarsen missed the primary endpoint in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial, which enrolled 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease.
- Pelacarsen is an antisense oligonucleotide, licensed from Ionis Pharmaceuticals, designed to suppress hepatic production of Lp(a), a lipid-protein particle linked to elevated cardiovascular risk.
- The drug achieved substantial lowering of Lp(a) levels in treated patients, but this biomarker reduction did not translate into a statistically significant drop in cardiovascular death, heart attack, stroke, or urgent revascularization versus placebo.
- The result is the first major late-stage setback for the emerging Lp(a)-lowering drug class, raising questions for rival programs from Amgen and Eli Lilly that use different modalities but showed larger Lp(a) reductions in earlier-stage studies.
- Novartis and Ionis had held global rights under a licensing and collaboration deal, with Ionis having discovered and advanced pelacarsen through early development before Novartis took it into Phase 3.
Pelacarsen just became the class's first hard-outcomes readout — and it missed, despite deep Lp(a) lowering. That's the uncomfortable part: this was the cleanest test yet of the Lp(a) causal hypothesis, and it didn't confirm it. Olpasiran (Amgen) and lepodisiran (Lilly) post larger percentage reductions in early studies, but bigger knockdown of the same biomarker doesn't guarantee outcomes benefit — their own outcomes trials now carry real doubt, not just execution risk. For Novartis, this was a marquee asset licensed from Ionis to anchor its cardiovascular pipeline; the miss removes a near-term blockbuster case and puts pressure on how the Ionis partnership economics get valued going forward. Biggest read-through: Lp(a) may need rethinking as a validated drug target, not just a biomarker to chase.